Jason R. Ruth

University of Pennsylvania — United States

Medicine · Health Sciences

16h-index2.9kcitations36works15.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Viral-associated cancers and disorders(14), Cancer, Hypoxia, and Metabolism(8), Lymphoma Diagnosis and Treatment(6), Cancer Cells and Metastasis(6), Microtubule and mitosis dynamics(5)

Publications36 total

Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy
Breast Cancer Research·2024· 15 citedOpen Access
Supplementary Methods from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Data from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Data from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Supplementary Methods from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Supplementary Figure Legend from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Supplementary Figures from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Supplementary Figure Legend from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Supplementary Figures from SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
2023Open Access
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Blood Advances·2021· 45 citedOpen Access
Cellular dormancy in minimal residual disease following targeted therapy
Breast Cancer Research·2021· 42 citedOpen Access
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
Cell Reports Medicine·2020· 32 citedOpen Access
Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
Blood·2019· 1 cited
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease
Journal of Clinical Investigation·2019· 135 citedOpen Access
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
PLoS ONE·2019· 41 citedOpen Access
Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease
Blood·2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Blood·2018· 395 citedOpen Access
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
American Journal of Hematology·2018· 82 citedOpen Access
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
Blood·2017· 592 citedOpen Access
Rare disease research requires (and benefits from) global collaboration: three examples from the Castleman Disease Collaborative Network
Revista de Medicina·2016Open Access
page 1 of 2Next →

Frequent Co-authors

David C. Fajgenbaum(14), Lewis A. Chodosh(13), Dhruv K. Pant(12), Frits van Rhee(11), Tien-Chi Pan(11), James V. Alvarez(10), Kristi R. Chakrabarti(9), Sheila K. Pierson(8), Yi Feng(8), Christopher S. Nabel(6), Alexander Fosså(6), Amy Liu(5), Raj Jayanthan(5), Arthur H. Rubenstein(5), Thomas S. Uldrick(4), Vera P. Krymskaya(4), Amy Chadburn(4), Razelle Kurzrock(4), Dustin Shilling(4), Katie Stone(4)